Management of Anticoagulation in AFib with NSTEMI

Rationale for DOAC in AFib with NSTEMI

The European Society of Cardiology recommends oral anticoagulation for patients with AFib at elevated thromboembolic risk (CHA2DS2-VA score ≥2) to prevent ischemic stroke and thromboembolism 1
The European Society of Cardiology recommends DOACs in preference to vitamin K antagonists (VKAs) for stroke prevention in eligible AFib patients, except those with mechanical heart valves or moderate-to-severe mitral stenosis 3
For patients with AFib and acute coronary syndrome (including NSTEMI), the recommended approach is an oral anticoagulant (preferably DOAC) plus a P2Y12 inhibitor (preferably clopidogrel) 4

For patients with AFib and NSTEMI requiring immediate intervention, initial IV unfractionated heparin or LMWH (like enoxaparin) should be administered, according to the European Heart Journal 5

The European Heart Journal recommends transitioning to a DOAC for long-term management of AFib patients initially treated with heparin/LMWH 5
Early cessation (≤1 week) of aspirin and continuation of an oral anticoagulant (preferably DOAC) with a P2Y12 inhibitor (preferably clopidogrel) for up to 12 months is recommended in AFib patients with ACS, as per the European Heart Journal 4

After 12 months, antiplatelet therapy should be discontinued and the patient should remain on DOAC monotherapy for stroke prevention in AFib, according to the European Heart Journal 4
Antiplatelet therapy beyond 12 months is not recommended in stable patients with chronic coronary disease treated with oral anticoagulation, as stated by the European Heart Journal 4

DOACs have demonstrated at least non-inferior efficacy compared to warfarin for prevention of thromboembolism, with 50% reduction in intracranial hemorrhage, as reported by the European Heart Journal 3
Meta-analyses show that standard DOAC treatment compared with warfarin reduces the risk of stroke or systemic embolism (HR, 0.81), all-cause mortality (HR, 0.90), and intracranial bleeding (HR, 0.48), according to the European Heart Journal 3
DOACs have a wider therapeutic window than heparin and don't require the frequent monitoring needed with heparin therapy, as stated by the European Heart Journal 5

Adding antiplatelet treatment to anticoagulation is not recommended in patients with AFib for the goal of preventing ischemic stroke or thromboembolism beyond the recommended duration after ACS, as per the European Heart Journal 1, 2
A reduced dose of DOAC therapy is not recommended unless patients meet specific criteria for dose reduction (such as renal impairment, age ≥80 years, or low body weight), according to the European Heart Journal 1, 3
Assessment of renal function is essential before initiating a DOAC, with dose adjustments required for patients with renal impairment, as stated by the American College of Cardiology 6
DOACs are not recommended in patients with severe renal impairment (CrCl <30 mL/min), as reported by the European Heart Journal 7